GLP-1 Eligibility: BMI, Comorbidities, and FDA Labeling

GLP-1 eligibility is not just "anyone who wants to lose weight." FDA labeling, clinical guidelines, and insurance formularies each apply their own rules. Our GLP-1 eligibility calculator walks you through the FDA-labeled criteria so you know what to discuss with a prescriber. This post explains the logic.

FDA-Labeled Indications for Chronic Weight Management

As of early 2026, two medications carry FDA indications specifically for chronic weight management in adults:

• Wegovy (semaglutide 2.4 mg) — approved 2021
• Zepbound (tirzepatide) — approved 2023

Liraglutide (Saxenda) is also approved for weight management but has been largely supplanted by the once-weekly options. Ozempic and Mounjaro are approved for type 2 diabetes, not weight management, though they contain the same active ingredients as Wegovy and Zepbound respectively.

The Core BMI Criteria

For adults, both Wegovy and Zepbound labels include the same framework:

• BMI ≥ 30 kg/m² (obesity), or
• BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity

BMI is calculated as weight in kilograms divided by height in meters squared. The CDC adult cutoffs classify 25-29.9 as overweight and 30+ as obesity.

Qualifying Comorbidities

FDA labeling and clinical guidelines commonly recognize:

• Hypertension (blood pressure ≥130/80 or taking antihypertensive medication)
• Type 2 diabetes (HbA1c ≥6.5% or on glucose-lowering medication)
• Prediabetes (HbA1c 5.7-6.4% or impaired fasting glucose)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease (prior MI, stroke, coronary artery disease)
• Non-alcoholic fatty liver disease / MASLD
• Polycystic ovary syndrome (PCOS) with metabolic features
• Osteoarthritis weight-bearing joints

Insurance formularies may be stricter — some require objective documentation (lab values, sleep study reports) rather than self-report.

Adolescents

Wegovy is approved for adolescents aged 12 and older with a BMI at or above the 95th percentile for age and sex (obesity classification). This is a relatively new indication, and pediatric prescribing is typically managed by specialists.

Cardiovascular Risk Indication

In 2024, semaglutide 2.4 mg (Wegovy) received an additional FDA indication: reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. This expanded indication may affect Medicare coverage (which typically excludes weight-management-only prescriptions) and opens the medication to a different patient population.

Who Is Generally Excluded

FDA labels list contraindications and precautions that typically rule out or require caution with GLP-1 therapy:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to the drug
• History of pancreatitis (caution, not absolute contraindication)
• Active gallbladder disease (caution)
• Severe gastroparesis or other significant GI motility disorders
• Pregnancy or planning pregnancy (discontinuation typically recommended)
• Type 1 diabetes (not studied for this indication)

Additionally, patients with severe kidney or liver disease, those on certain medications that affect insulin or GI motility, and those with eating disorders should have careful evaluation.

Insurance and Prior Authorization

Even if you meet FDA criteria, insurance often adds hoops:

• Documented lifestyle intervention — often 3-6 months of supervised diet, exercise, and behavior change before authorization
• Step therapy — requiring failure of older agents like phentermine or orlistat
• BMI documentation — requiring recent clinical measurement, not self-report
• Specific comorbidity documentation — lab values, imaging, or specialist notes
• Renewal criteria — demonstrating sustained weight loss (often ≥5% at 6-12 months) for continued coverage

Many plans explicitly exclude "drugs used for weight loss" regardless of FDA labeling.

BMI Nuances

BMI is an imperfect tool. A muscular athlete with a BMI of 28 and no metabolic issues likely does not need GLP-1 therapy. Conversely, someone with a BMI of 26 and active type 2 diabetes plus sleep apnea may benefit significantly. Guidelines from the American Association of Clinical Endocrinology (AACE) and others increasingly emphasize body-composition and metabolic context, not just BMI in isolation.

Asian and South Asian populations in particular show cardiometabolic risk at lower BMI thresholds — some guidelines use BMI 25+ as obesity for these populations.

Off-Label Prescribing

Some prescribers use Ozempic or Mounjaro off-label for weight management, since they contain the same active ingredients as Wegovy and Zepbound. This is legal but may affect insurance coverage (off-label weight-loss use is often not reimbursed) and quantity/supply availability. This is a decision for you and your prescriber.

Next Steps

Run your numbers through the GLP-1 eligibility calculator to see whether you meet FDA-labeled criteria. If you do, the next step is a conversation with a licensed prescriber — ideally one familiar with obesity medicine — who can evaluate your full medical history, discuss benefits and risks, and determine whether therapy is appropriate and how insurance coverage looks for your specific plan.